ALZN — Alzamend Neuro Income Statement
0.000.00%
Last trade - 00:00
- $4.94m
- $4.74m
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.01 | 4.42 | 4.89 | 12.3 | 14.9 |
Operating Profit | -5.01 | -4.42 | -4.89 | -12.3 | -14.9 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4.86 | -4.41 | -5.05 | -12.4 | -14.9 |
Net Income After Taxes | -4.86 | -4.41 | -5.05 | -12.4 | -14.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.86 | -4.41 | -5.05 | -12.4 | -14.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.86 | -4.41 | -5.05 | -12.4 | -14.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.859 | -0.779 | -0.902 | -2.08 | -2.29 |
Dividends per Share |